Negative innovation: when patents are bad for patients

Negative innovation: when patents are bad for patients

Incentives in patent law have driven innovation into spaces that are affirmatively harmful to patients, and patentees are discouraged from taking steps to improve the product so as to prevent adverse health outcomes.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biotechnology 2021-08, Vol.39 (8), p.914-916
Hauptverfasser: Feldman, Robin C, Hyman, David A, Price, W. Nicholson, II, Ratain, Mark J
Format: Artikel
Sprache:eng
Schlagworte:
Drug dosages
Evaluation
FDA approval
Incentives
Innovations
Laws, regulations and rules
Leukemia
Patent law
Patent policy
Patient compliance
Patients
Response rates
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Incentives in patent law have driven innovation into spaces that are affirmatively harmful to patients, and patentees are discouraged from taking steps to improve the product so as to prevent adverse health outcomes.
ISSN:1087-0156
1546-1696
DOI:10.1038/s41587-021-00999-0